Navigation Links
Alliqua to Explore Business Development Efforts for Hydrogel Transdermal Delivery Platform in the Cosmeceutical Industry
Date:11/19/2012

NEW YORK, Nov. 19, 2012 /PRNewswire/ -- Alliqua, Inc. (OTCQB:ALQA) ("Alliqua" or the "Company"), a biopharmaceutical company focused on the development, manufacturing and distribution of proprietary transdermal wound care and drug delivery technologies, today announced the Company's exploration of business development efforts for its proprietary transdermal delivery platform in the cosmeceutical industry.

According to market research data from the Freedonia Group, the cosmeceutical market reached $6.4 billion in 2010 and is projected to grow to $8.5 billion by 2015, largely fueled by consumers searching to stave off the physical signs of aging.  While this market has traditionally been focused on consumers aged 45 and older, recent trends show younger consumers are seeking out anti-aging products designed to prevent or treat even early signs of aging including fine lines and wrinkles.  Alliqua believes its transdermal platform is ideal for administering the key ingredients of these anti-aging products more effectively to targeted areas of the body.  In doing so, the Alliqua technology has the potential to greatly enhance the performance of a variety of cosmeceutical products across a broad spectrum of areas.  Additionally, the time to market for cosmeceutical products is typically much shorter than for traditional drug delivery making it a very attractive business opportunity for Alliqua.

James Sapirstein, CEO of Alliqua stated, "The cosmeceutical industry represents a vast market opportunity for our proprietary transdermal platform.  What is equally as exciting for Alliqua is that with our hydrogel technology, we can reach the market in a relatively short time frame when compared to traditional drug delivery platforms.  We intend to aggressively pursue partnerships with various manufacturers to help them increase the effectiveness of their products and achieve more optimal results for the consumer.  By doing this we have the potential to build a highly profitable business segment for Alliqua in the cosmeceutical marketplace."

About Alliqua, Inc.

Alliqua, Inc. (ALQA) ("Alliqua") is a biopharmaceutical company focused on the development, manufacturing and distribution of our proprietary transdermal wound care and drug delivery technologies. Alliqua's leading technology platform produces hydrogels, a 3-dimensional cross-linked network of water soluble polymers capable of numerous chemical configurations.

Alliqua currently markets its new line of 510K FDA approved hydrogel products for wound care under the SilverSeal® brand.  The Company's electron beam production process located at its 16,000 square foot GMP manufacturing facility in Langhorne, PA, allows Alliqua to aggressively develop and custom manufacture a wide variety of hydrogels. Alliqua's hydrogels can be customized for various transdermal applications to address market opportunities in the treatment of wounds as well as the delivery of numerous drugs or other agents for the pharmaceutical and cosmetic industries.  Additionally, the Company's drug delivery platform, in combination with certain drugs, provides pharmaceutical companies with potential greater patient compliance and could potentially extend the life of valuable drug patents.

For additional information, please visit www.alliqua.com. To receive future press releases via email, please visit: http://alliqua.com/index.php?page=investor-alerts.

Any statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration.

Legal Notice Regarding Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties outside of the our control that can make such statements untrue, including, but not limited to, inadequate capital, adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, termination of contracts or agreements, technological obsolescence of our products, technical problems with our research and products, price increases for supplies and components, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our ongoing research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and/or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that we will be able to develop new products on the basis of our technologies. In addition, other factors that could cause actual results to differ materially are discussed in our Annual Report on Form 10-K filed with the SEC on March 29, 2012 and our most recent Form 10-Q filings with the SEC. Investors and security holders are urged to read these documents free of charge on the SEC's web site at www.sec.gov. We undertake no obligation to publicly update or revise our forward-looking statements as a result of new information, future events or otherwise.

Contact:

Alliqua, Inc.
Steven Berger
646-218-1450 

 


'/>"/>
SOURCE Alliqua, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Alliqua Appoints Dr. Joseph Laudano as Vice President of Medical Affairs to Support the Market Expansion of Alliquas SilverSeal Products and Future Clinical Development
2. Advanced Radiotherapy Techniques Explored at Educational Events in India
3. Frost & Sullivan: Label-Free Technology is a High Potential Market with Myriad Unexplored Applications
4. Meridian Labs Hires Investment Bank to Explore Strategic Opportunities
5. Biogen Idec and Regulus Therapeutics Form Collaboration to Explore microRNA Biomarkers for Disease Monitoring and Response to Therapy
6. MediSapiens Launches OncoGenomics Explorer, First-in-Kind Cloud Computing Application for Personalized Genomics
7. Pharmaceutical Industry Service Company Awarded The UKs Most Prestigious Business Accolade in Recognition of Outstanding Achievement in International Trade
8. CareFusion to Sell Neurodiagnostic Business to Natus Medical for $58 Million
9. Nominations Open for San Francisco Business Times Health Care Heroes Awards
10. Bayer Employees Named Rising Stars by Healthcare Businesswomens Association
11. Amendia, Inc. and Medline Industries, Inc. Announce Investment and Strategic Business Alliance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... , March 24, 2017 FinancialBuzz.com News Commentary   ... Medical cannabis products around the ... Inc., projects that the global medical cannabis market will reach a value ... is a major market for the new growing industry. By the end ... legally buy and sell medical cannabis. More conservative states like ...
(Date:3/24/2017)... A ReportsnReports.com report says, over the recent ... the global sales of Adcetris and Kadcyla have been witnessing rapid ... conjugates market is driven by large number of ADC drugs in ... offered by ADCs. ... Browse 3 Tables and 94 Figures, 10 Major Company Profiles, spread ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... Global Strategic Business Report" report to their offering. ... The report provides separate comprehensive analytics for ... Europe , Asia-Pacific , ... are provided for the period 2015 through 2022. Also, a six-year historic ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... March 24, 2017 , ... Digital Scientists, a software innovation ... the opening of a Greenville, South Carolina location. The lab has set ... Greenville. , “We’ve been working with South Carolina clients for years from our office ...
(Date:3/24/2017)... Lake Orion, MI (PRWEB) , ... March 24, ... ... providing insurance assistance, financial planning, and related services to families and business owners ... charity initiative aimed at feeding regional families struggling with financial difficulties. , The ...
(Date:3/24/2017)... ... March 24, 2017 , ... On June 9, 2017, ... Claims Litigation seminar in Chicago, Illinois. She will present on: , Filing ... litigated under ERISA involve claims for long-term disability benefits. This session will ...
(Date:3/24/2017)... ... March 24, 2017 , ... Judy Buchanan, co-owner of Serenity ... MD. Judy says, “I am passionate about sharing Reiki as a holistic, complementary ... and challenging time.” , A Certified Medical Reiki™ Master trained by Raven Keys ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Adventures of Joey, The Dog Who Barks ... lives his life to the fullest, as God intended. “The Adventures of Joey, The ... mother and grandmother pursuing her passion for writing, especially about truth and human behavior. ...
Breaking Medicine News(10 mins):